Purine nucleoside substituted at N6, modified at position 2, is a β-D-2'-deoxy-2'α-fluoro-2'-β-C substituted for the treatment of hepatitis C virus (HCV) and pharmaceuticals containing it.

VN10061416BActive Publication Date: 2026-10-01ATEA PHARMACEUTICALS INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: VN1202301812
Authority / Receiving Office: VN · VN
Patent Type: Patents
Current Assignee / Owner
Filing Date: 2016-03-07
Publication Date: 2026-10-01
Estimated Expiration: 2036-03-07

Application Information

Patent Timeline

07 Mar 2016

Application

VN1202301812

01 Oct 2026

Publication

VN10061416B

Inventors: SOMMADOSSI, Jean-Pierre; MOUSSA, Adel

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The invention relates to a compound with the structural formula (A): or pharmaceutical salts or preparations containing them for the treatment of animals infected with or exposed to HCV or other disorders described more fully in the description.

Need to check novelty before this filing date? Find Prior Art